Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients 12 years of age and older~* Must be in generally good health~* Must meet minimum symptom requirements, as specified in protocol~* Must be willing and able to provide informed consent and participate in all study procedures~* 2-year history of PAR~* Positive skin test to cockroach, dust mite, mold or cat/dog dander~Exclusion Criteria:~* On nasal examination, presence of any nasal mucosal erosion, nasal ulceration or nasal septal perforation at the screening or randomization visit~* Nasal diseases likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa, significant polyposis or nasal structural abnormalities~* Nasal surgery or sinus surgery within the previous year~* The use of any investigational drug within 30 days~* Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose~* Women who are pregnant or nursing~* Women of child-bearing potential who are not abstinent and not practicing a medically acceptable method of contraception~* Respiratory tract infection within 2 weeks of screening~* Respiratory tract infections requiring oral antibiotic treatment within 2 weeks of screening~* Patients with asthma with the exception of mild, intermittent~* Significant pulmonary disease including COPD~* Patients with arrhythmia~* Patients with a known history of alcohol or drug abuse~* Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor may significantly alter the absorption, distribution, metabolism or excretion of study drug.~* Clinically relevant abnormal physical findings within one week of randomization~* Overnight abscences from home for more than 3 nights~* Employees of the research center or private practice and family members are excluded~* Patients who received prohibited medications within specified timepoints in protocol.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): 0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
- 3 (Type: EXPERIMENTAL): 0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).